MCLA-158
PreclinicalSmall molecule
MCLA-158 is one of 26 small molecule programs targeting Advanced/Metastatic Solid Tumors. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
41 competitors in Advanced/metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Fludara
SanofiPhase 2
Herceptin
RochePhase 2
Tagrisso
AstraZenecaPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Albumin-Bound Paclitaxel
Bristol-Myers SquibbPhase 2
BNT327
BioNTechPhase 2
HLX43
Shanghai Henlius BiotechPhase 2
Serplulimab
Shanghai Henlius BiotechPhase 2
Abraxane
Bristol-Myers SquibbPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MCLA-158. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMerus B.V.